BioStem Technologies, Inc. (BSEM) Stock

About BioStem Technologies, Inc.

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

BioStem Technologies, Inc. is headquartered in US.

BioStem Technologies, Inc. (BSEM) stock trades at $4.01 with a market capitalization of $68.11M. The stock is valued at a price-to-earnings (P/E) ratio of -3.40, price-to-book of 2.12, price-to-sales of -3.60. Over the past 52 weeks the stock has ranged between $3.09 and $12.00, and currently trades 66.6% below its 52-week high.

On profitability, BioStem Technologies, Inc. generates a return on equity (ROE) of -47.03%, return on capital employed of -46.45%, an operating margin of 78.38%, a net profit margin of 105.15%.

Official website: biostemtechnologies.com